Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
Hospitalized patients with COPD or interstitial lung disease are not frequently prescribed opioids for severe breathlessness, and those who are prescribed opioids for breathlessness do not receive timely follow-up.
A new genomic classifier added to bronchoscopic lung cryobiopsy increased the diagnostic confidence of physicians for interstitial lung disease.
Researchers evaluated the effect of anti-acid treatment on disease progression in systemic sclerosis interstitial lung disease.
Lung ultrasound B-lines can depict modifications in the lung parenchyma of patients with systemic sclerosis and may be an independent predictor of additional pulmonary deterioration in individuals with the disease.
Optimal treatment of patients with EGFR-TKI–associated ILD is based on rapid diagnosis and the timely implementation of specific interventions.
Inhaled nitric oxide 45 mcg/kg of ideal body weight per hour was effective for improving physical activity in patients at risk for pulmonary hypertension associated with fibrotic interstitial lung disease.
Both body mass index and changes in weight have been linked to 1-year mortality risk in patients with fibrotic interstitial lung disease.
Computed tomography densitometry may serve as an additional marker of disease severity in interstitial lung disease.
A link between homocitrullination and the development of interstitial lung disease in patients with rheumatoid arthritis may exist.
